GSK plc (LSE/NYSE: LON:GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy, may be effective in a broader adult population.
Currently approved for use in individuals aged 60 and above in over 50 countries, and for those aged 50-59 at increased risk in the US and Europe, the new data could potentially extend protection against RSV to adults aged 18-49 with underlying medical conditions and immunocompromised adults.
The phase IIIb trial (NCT06389487) demonstrated that a single dose of Arexvy elicited a robust immune response in adults aged 18-49 at increased risk for RSV lower respiratory tract disease (RSV-LRTD), comparable to the response seen in older adults.
The phase IIb trial (NCT05921903) showed that one dose of the vaccine generated a strong immune response in immunocompromised adults, with a second dose producing similar results to one dose in healthy older adults.
RSV is a significant cause of respiratory illness globally, particularly impacting immunocompromised individuals and those with conditions such as COPD, asthma, and diabetes. The US alone has over 21 million adults aged 18-49 with at least one risk factor for RSV.
The safety profile of Arexvy in the trials was consistent with previous phase III results, with the most common adverse events being pain at the injection site, fatigue, myalgia, arthralgia, and headache, which were generally mild and transient.
The findings from these studies will be presented at upcoming medical conferences and submitted for publication. GSK also plans to submit the final data to the FDA and other regulatory bodies to support potential label updates for Arexvy.
GSK's RSV vaccine combines the recombinant RSV glycoprotein F with the company's proprietary AS01E adjuvant. The vaccine's use should align with official recommendations, and while it may not elicit a protective immune response in all vaccinees, it is approved for RSV-LRTD prevention in older adults in multiple countries, with regulatory reviews for broader indications ongoing.
This news is based on a press release statement and ongoing clinical trial data. Final results will be available upon the trials' completion, expected in 2025.
In other recent news, GSK has made significant strides in its ongoing affairs. The company reported promising results from its phase III ANCHOR trials for depemokimab, a treatment for chronic rhinosinusitis with nasal polyps. The trials showed a significant reduction in nasal polyp size and nasal obstruction, supporting the potential benefits of the drug for patients suffering from this condition.
GSK also announced a settlement of up to $2.2 billion for U.S. lawsuits alleging that its now-discontinued heartburn medication Zantac was carcinogenic. This figure, which is lower than some market analysts had predicted, covers approximately 93% of the pending cases against GSK.
Analysts from Jefferies indicated that this move should alleviate most uncertainties affecting the company's stock due to the Zantac-related legal issues.
Jefferies anticipates that GSK's Q3 sales and profits may fall short of consensus estimates due to the weaker-than-expected performance of US Arexvy. However, the company is expected to reaffirm its 2024 outlook.
These are recent developments in the company's operations.
InvestingPro Insights
GSK's latest clinical trial data for Arexvy aligns well with the company's strong market position and financial performance. According to InvestingPro data, GSK boasts a market capitalization of $76.96 billion and has demonstrated solid revenue growth, with a 9.84% increase in the most recent quarter. This growth trajectory could be further bolstered by the potential expansion of Arexvy's target population.
InvestingPro Tips highlight GSK as a "prominent player in the Pharmaceuticals industry," which is evident from its innovative RSV vaccine development. The company's ability to maintain dividend payments for 24 consecutive years, coupled with a current dividend yield of 4.06%, underscores its financial stability and commitment to shareholder returns. This could be particularly appealing to investors looking for steady income alongside potential growth from expanded vaccine applications.
The company's profitability over the last twelve months and analysts' predictions of continued profitability this year suggest that GSK is well-positioned to support ongoing research and development efforts, such as the Arexvy trials. With an adjusted P/E ratio of 8.64, GSK may be considered undervalued relative to its earnings potential, especially if Arexvy receives approval for broader use.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips and insights on GSK's financial health and market position. The platform provides a total of 11 tips for GSK, which can help investors make more informed decisions about the company's prospects in light of its expanding vaccine portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.